ACLARIS THERAPEUTICS INC (ACRS) Fundamental Analysis & Valuation

NASDAQ:ACRS • US00461U1051

Current stock price

3.8 USD
-0.4 (-9.52%)
At close:
3.8782 USD
+0.08 (+2.06%)
After Hours:

This ACRS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ACRS Profitability Analysis

1.1 Basic Checks

  • In the past year ACRS has reported negative net income.
  • In the past year ACRS has reported a negative cash flow from operations.
  • ACRS had negative earnings in each of the past 5 years.
  • In the past 5 years ACRS always reported negative operating cash flow.
ACRS Yearly Net Income VS EBIT VS OCF VS FCFACRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • ACRS has a Return On Assets of -40.46%. This is comparable to the rest of the industry: ACRS outperforms 41.67% of its industry peers.
  • ACRS has a Return On Equity of -62.98%. This is comparable to the rest of the industry: ACRS outperforms 46.35% of its industry peers.
Industry RankSector Rank
ROA -40.46%
ROE -62.98%
ROIC N/A
ROA(3y)-48.41%
ROA(5y)-43.11%
ROE(3y)-68.06%
ROE(5y)-58.84%
ROIC(3y)N/A
ROIC(5y)N/A
ACRS Yearly ROA, ROE, ROICACRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • ACRS's Gross Margin of 6.93% is in line compared to the rest of the industry. ACRS outperforms 50.52% of its industry peers.
  • In the last couple of years the Gross Margin of ACRS has declined.
  • The Profit Margin and Operating Margin are not available for ACRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 6.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-51.26%
GM growth 5Y-19.77%
ACRS Yearly Profit, Operating, Gross MarginsACRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ACRS Health Analysis

2.1 Basic Checks

  • ACRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ACRS has more shares outstanding
  • The number of shares outstanding for ACRS has been increased compared to 5 years ago.
  • There is no outstanding debt for ACRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACRS Yearly Shares OutstandingACRS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ACRS Yearly Total Debt VS Total AssetsACRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • ACRS has an Altman-Z score of -4.16. This is a bad value and indicates that ACRS is not financially healthy and even has some risk of bankruptcy.
  • ACRS's Altman-Z score of -4.16 is on the low side compared to the rest of the industry. ACRS is outperformed by 61.98% of its industry peers.
  • ACRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.16
ROIC/WACCN/A
WACC9.25%
ACRS Yearly LT Debt VS Equity VS FCFACRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 3.36 indicates that ACRS has no problem at all paying its short term obligations.
  • ACRS has a Current ratio (3.36) which is comparable to the rest of the industry.
  • ACRS has a Quick Ratio of 3.36. This indicates that ACRS is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ACRS (3.36) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.36
Quick Ratio 3.36
ACRS Yearly Current Assets VS Current LiabilitesACRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ACRS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 64.90% over the past year.
  • ACRS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -58.20%.
  • The Revenue has been growing slightly by 3.85% on average over the past years.
EPS 1Y (TTM)64.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.16%
Revenue 1Y (TTM)-58.2%
Revenue growth 3Y-35.93%
Revenue growth 5Y3.85%
Sales Q2Q%-85.94%

3.2 Future

  • ACRS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.43% yearly.
  • Based on estimates for the next years, ACRS will show a very strong growth in Revenue. The Revenue will grow by 72.73% on average per year.
EPS Next Y-23.87%
EPS Next 2Y-15.19%
EPS Next 3Y-15.57%
EPS Next 5Y2.43%
Revenue Next Year-40.47%
Revenue Next 2Y-21.23%
Revenue Next 3Y-16.35%
Revenue Next 5Y72.73%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ACRS Yearly Revenue VS EstimatesACRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
ACRS Yearly EPS VS EstimatesACRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. ACRS Valuation Analysis

4.1 Price/Earnings Ratio

  • ACRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ACRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRS Price Earnings VS Forward Price EarningsACRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRS Per share dataACRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as ACRS's earnings are expected to decrease with -15.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.19%
EPS Next 3Y-15.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ACRS Dividend Analysis

5.1 Amount

  • No dividends for ACRS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACRS Fundamentals: All Metrics, Ratios and Statistics

ACLARIS THERAPEUTICS INC

NASDAQ:ACRS (4/6/2026, 8:19:51 PM)

After market: 3.8782 +0.08 (+2.06%)

3.8

-0.4 (-9.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-06
Earnings (Next)05-06
Inst Owners69.98%
Inst Owner Change0%
Ins Owners2.52%
Ins Owner Change4.45%
Market Cap458.28M
Revenue(TTM)7.83M
Net Income(TTM)-64.92M
Analysts85.33
Price Target8.35 (119.74%)
Short Float %4%
Short Ratio1.75
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.14%
Min EPS beat(2)-4.58%
Max EPS beat(2)12.85%
EPS beat(4)2
Avg EPS beat(4)3.06%
Min EPS beat(4)-4.58%
Max EPS beat(4)12.85%
EPS beat(8)4
Avg EPS beat(8)-260.47%
EPS beat(12)8
Avg EPS beat(12)-162.86%
EPS beat(16)12
Avg EPS beat(16)-117.44%
Revenue beat(2)1
Avg Revenue beat(2)47.86%
Min Revenue beat(2)-34.5%
Max Revenue beat(2)130.22%
Revenue beat(4)3
Avg Revenue beat(4)33.51%
Min Revenue beat(4)-34.5%
Max Revenue beat(4)130.22%
Revenue beat(8)6
Avg Revenue beat(8)67.94%
Revenue beat(12)9
Avg Revenue beat(12)122.69%
Revenue beat(16)11
Avg Revenue beat(16)174.6%
PT rev (1m)2.34%
PT rev (3m)6.79%
EPS NQ rev (1m)0.9%
EPS NQ rev (3m)-14.28%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-47.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-35.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 58.56
P/FCF N/A
P/OCF N/A
P/B 4.45
P/tB 4.45
EV/EBITDA N/A
EPS(TTM)-0.53
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.06
BVpS0.85
TBVpS0.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.46%
ROE -62.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 6.93%
FCFM N/A
ROA(3y)-48.41%
ROA(5y)-43.11%
ROE(3y)-68.06%
ROE(5y)-58.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-51.26%
GM growth 5Y-19.77%
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 207.93%
Cap/Sales 12.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.36
Quick Ratio 3.36
Altman-Z -4.16
F-Score3
WACC9.25%
ROIC/WACCN/A
Cap/Depr(3y)1604.01%
Cap/Depr(5y)984.39%
Cap/Sales(3y)69.4%
Cap/Sales(5y)42.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.16%
EPS Next Y-23.87%
EPS Next 2Y-15.19%
EPS Next 3Y-15.57%
EPS Next 5Y2.43%
Revenue 1Y (TTM)-58.2%
Revenue growth 3Y-35.93%
Revenue growth 5Y3.85%
Sales Q2Q%-85.94%
Revenue Next Year-40.47%
Revenue Next 2Y-21.23%
Revenue Next 3Y-16.35%
Revenue Next 5Y72.73%
EBIT growth 1Y-38.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.84%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-134.68%
OCF growth 3YN/A
OCF growth 5YN/A

ACLARIS THERAPEUTICS INC / ACRS Fundamental Analysis FAQ

What is the fundamental rating for ACRS stock?

ChartMill assigns a fundamental rating of 3 / 10 to ACRS.


What is the valuation status of ACLARIS THERAPEUTICS INC (ACRS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ACLARIS THERAPEUTICS INC (ACRS). This can be considered as Overvalued.


What is the profitability of ACRS stock?

ACLARIS THERAPEUTICS INC (ACRS) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ACLARIS THERAPEUTICS INC?

The Earnings per Share (EPS) of ACLARIS THERAPEUTICS INC (ACRS) is expected to decline by -23.87% in the next year.